aidsmap news story
Lenacapavir – the highly effective HIV prevention medication that only requires two shots a year – is currently rolling out across African countries with a high burden of HIV. Initial data from countries such as Eswatini, Malawi, Mozambique and Kenya were shared at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Demand is already outpacing supply in some instances, with ambitious targets set for 2026 and beyond.
Countries are mostly obtaining lenacapavir through a programme set up between the US State Department, the Global Fund and Gilead Sciences. Gilead sells the drug at no profit, but at an undisclosed cost.
The programme aims to reach at least three million people with lenacapavir by the end of 2028. This massive drive is in partnership with national governments, with high-, middle- and low-income countries simultaneously launching lenacapavir PrEP – a rare occurrence.
Read the full news story here.
View all aidsmap reports from AIDS 2026
SEE ALSO:
Source : aidsmap
Related HIV and Co-Infections News
-
[AIDS 2026] aidsmap: Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing
-
[AIDS 2026] Countries in Latin America and the Caribbean helped build the future of HIV prevention. But will they be able to benefit from it?
-
[AIDS 2026] [Report] UNAIDS: Global HIV response falters as reemergence looms
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.